Isomorphic says its AI is proven; $2.7 billion rides on a 31 December deadline
Isomorphic Labs' president says its AI hypothesis "has been proven." The ledger shows $2.7 billion raised, $82.5 million banked from partners, no drug named and no trial started, with the company's own year-end deadline 13 weeks away.
Vincent Jiang · 3 min read
The charge: proven, with 13 weeks left
On 29 September Isomorphic Labs president Max Jaderberg declared the company's founding wager settled: "Our hypothesis has been proven" 12. The manifesto shows IsoDDE, the drug design engine, searching chemical space for an unnamed "Target D" in two to four days, against a published reference molecule its authors estimate took three to five years of work 1. The company's own test sits 13 weeks out: a first clinical trial by the end of 2026, a deadline already moved once from late 2025 2.
The evidence admitted: $2.7 billion in, $82.5 million banked
About $2.7 billion of outside money has arrived since 2025, a $600 million first round and then a $2.1 billion Series B in May led by Thrive Capital with Alphabet, GV and Temasek 24. The disclosed partner income, ever, is $82.5 million in upfronts: $45 million from Eli Lilly and $37.5 million from Novartis, both signed January 2024, against up to $2.9 billion in contingent milestones 2. Not one milestone payment has been reported 2.
The disclosure record is thin. As of 30 September, Isomorphic had named no candidate, named no target, given no program count, filed no IND and started no trial; the only pipeline detail on offer is two focus areas, oncology and immunology 2.
Isomorphic has banked $82.5M of partner cash; not one milestone paid
Data
| Value | |
|---|---|
| Funding raised since 2025 | $2,700M |
| Lilly milestones (ceiling) | $1,700M |
| Novartis milestones (ceiling) | $1,200M |
| Lilly upfront (paid 2024) | $45M |
| Novartis upfront (paid 2024) | $37.5M |
The exhibits: partners who come back
Pharma keeps signing back. Novartis added up to three programs a year after its first deal, and Johnson & Johnson signed a cross-modality, multi-target collaboration on 20 January 2026, terms undisclosed 25. In February the company published benchmarks claiming more than double AlphaFold 3's accuracy on hard protein-ligand cases 2.
The cross-examination: the candidate was Insilico's
Skeptic Melinda Chu's line is blunt: "you can't cure a disease without a drug" 2. On 30 September a crypto news wire ran a nomination under Isomorphic's name: ISM1354, a GIPR antagonist for obesity and type 2 diabetes, a 34th preclinical candidate since 2021 6. The release belongs to Insilico Medicine, which took rentosertib from target to Phase 1 in under 30 months and is now in Phase 3 28. Insilico, listed in Hong Kong, booked its first profitable half-year in 2026 on about $106 million of revenue 8.
The trade: three tickers hold the test
Eli Lilly (LLY) and Novartis (NVS) paid to see the internal data and hold the milestone schedules, Lilly up to $1.7 billion and Novartis up to $1.2 billion 2. A first milestone cheque would be the first independent confirmation the engine works 2. Alphabet (GOOGL) owns the lab outright and funded it before outside money arrived 23. The listed comp is Schrödinger (SDGR): $199.5 million of 2025 software revenue against a $103 million net loss, and it sells what Isomorphic does not 2. Miss 31 December again and the AI premium deflates; hit it and the partner programs move.
The verdict watch: 31 December
Three receipts would settle the argument: an IND filing, a trial start, or the first milestone payment 2. The trade watches the same list, so milestone news or an IND out of the Lilly and Novartis programs before 31 December is the signal. Chu predicts no trial this year, and possibly not in 2027; the company's own clock says otherwise 2.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.
